Max Chat
Calendrier des promotions Vincerx Pharma, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Paramètres de base
IPO date
2020-05-27
ISIN
US92731L1061
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 3.66 | 5 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -229.38 | 0 |
| ROE | -431.29 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0795 | 10 |
| Debt/Ratio | 0.3126 | 10 |
| Debt/Equity | 1.94 | 7 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 194.05 | 10 |
| Rentabilité EPS, % | 676.72 | 10 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 0.055 $ | 0 $ | 0 $ | -5.45 % | 0 % | 0 % |
| common.calendar.number_days.7d | 0.0485 $ | 0 $ | 0 $ | +7.22 % | 0 % | 0 % |
| common.calendar.number_days.30d | 0.0495 $ | 0.052 $ | 0.055 $ | +5.05 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.265 $ | 0.0421 $ | 0.275 $ | -80.38 % | 0 % | 0 % |
| common.calendar.number_days.180d | 1.4 $ | 0.0421 $ | 3.05 $ | -96.29 % | 0 % | 0 % |
| common.calendar.number_days.1y | 0.79 $ | 0.0421 $ | 15.6 $ | -93.42 % | 0 % | 0 % |
| common.calendar.number_days.3y | 1.63 $ | 0.0421 $ | 15.6 $ | -96.81 % | 0 % | 0 % |
| common.calendar.number_days.5y | 10.01 $ | 0.0421 $ | 25.9 $ | -99.48 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.0421 $ | 0.0421 $ | 25.9 $ | +130.64 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 1.56 $ | 0.0421 $ | 4.71 $ | -96.67 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman & CEO | 657.54k | 1965 (60 années) |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, COO, Secretary & Director | 591.54k | 1970 (55 années) |
| Mr. Alexander A. Seelenberger M.B.A. | Chief Financial Officer | 491.69k | 1979 (46 années) |
| Mr. Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer | 444.14k | 1960 (65 années) |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board | N/A | |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | N/A | |
| Ms. Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff | N/A | |
| Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | N/A | |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | N/A | |
| Ms. Karen Quarford M.B.A. | Vice President of Quality Operations & Compliance |
Informations sur l'entreprise
Adresse: United States, Palo Alto. CA, 260 Sheridan Avenue - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://vincerx.com
Site web: https://vincerx.com
